Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ProShares UltraPro QQQ ETF
TQQQ
5
ProShares UltraPro Short Dow30 ETF
SDOW
CN Stock MarketDetailed Quotes
688363 Bloomage Biotechnology Corporation Limited
- 52.58
- -0.12-0.23%
Market to Open Jun 17 09:30 CST
25.33BMarket Cap773.24P/E (TTM)
52.58High52.58Low44.27lotVolume52.58Open52.70Pre Close232.77KTurnover0.00%Turnover Ratio145.25P/E (Static)481.68MShares84.5952wk High3.66P/B25.33BFloat Cap42.5152wk Low63.24Limit Up481.68MShs Float313.10Historical High42.16Limit Down0.00%Amplitude42.51Historical Low0.38Dividend TTM52.58Avg Price0lotAsk0.72%Div Yield TTM100Lot Size0lotBid
Bloomage Biotechnology Corporation Limited News
Express News | Bloomage Biotechnology Corporation Limited: "Recombinant collagen" is rumored to be replacing "hyaluronic acid", lacking real data support.
Bloomage Biotechnology Corporation Limited (688363.SH): Elected Zhao Yan as Director.
On June 11, Gelonghui reported that Bloomage Biotechnology Corporation Limited (688363.SH) announced the convening of the first meeting of its third Board of Directors on June 11, 2025, during which the proposal concerning the election of the chairperson of the third Board of Directors was reviewed and approved, electing Ms. Zhao Yan as the chairperson of the third Board of Directors, with her term starting from the date of approval by the Board of Directors and lasting until the end of the term of the third Board of Directors.
Bloomage Biotechnology Corporation Limited (688363) deep report: HA leader innovation sets sail, life technology leads growth.
The global leader in hyaluronic acid sets sail again, eager for innovation and likely to welcome an operational turning point. Bloomage Biotechnology Corporation Limited is a platform company based on bioactive products, with a complete Industry Chain forming strong internal synergy. As the largest supplier of hyaluronic acid in the world.
The two major medical beauty giants are at odds: is it an industry competition or corporate growing pains | Focus
① The covert battle between the two companies, which has lasted for more than half a month, has escalated to a direct confrontation; ② Whether it is Bloomage Biotechnology Corporation Limited or Giant Bio, both companies may face the pain of competition or the pain of transformation.
The spillover effect of star stocks? The "new consumer four sisters" in the Hong Kong stock market ignite investment enthusiasm in the Sector, with leading companies poised for IPO.
On ****, the three major indices of the Hong Kong stock market opened low and rose high, and the stock prices of the "New Consumption F4" including POP MART, Mao Ge Ping, Mixue Group, and Laopu Gold reached a new historical high. Several individual stocks in various segments of the consumer field frequently rose in response to the stock price halo of leading star enterprises. On the IPO waiting list, there are many companies in each popular consumption segment ready to take off.
Express News | Bloomage Biotechnology Corporation Limited responds to recent controversies: collagen and "recombinant" collagen are not the same Concept.
Research Reports on digging gold | Changjiang Securities: Maintains Bloomage Biotechnology Corporation Limited 'Buy' rating, the medical beauty business has entered a positive development track after adjustments.
Changjiang Securities' research report indicates that Bloomage Biotechnology Corporation Limited (688363.SH) achieved a net income of 0.17 billion yuan in 2024, down 70.6% year-on-year; and a net income of 0.1 billion yuan in Q1 2025, down 58.1% year-on-year. The company focuses on overall resource utilization efficiency, promoting comprehensive internal management reform. After adjustments, the medical beauty business has entered a positive development track, and new products, Runzhigege and Runzhifeiran, are expected to drive growth and improve revenue and profit. It is believed that the company's raw material business has a solid market position and broad potential, while the contribution of the medical beauty business to the overall business is gradually increasing, with expectations for subsequent innovations in skin science.
Bloomage Biotechnology Corporation Limited (688363): The growth of the Medical terminal is impressive, while the skin care Business continues to adjust.
Event description: In 2024, the company achieved revenue of 5.37 billion yuan, a year-on-year decline of 11.6%; achieved net income attributable to the parent company of 0.17 billion yuan, a year-on-year decline of 70.6%. In Q4 2024, the company achieved revenue of 15.0.
Express News | Bloomage Biotechnology Corporation Limited: Sales of the ergothioneine raw material products have exceeded one million.
Bloomage Biotechnology Corporation Limited has refuted the "outdated theory" regarding hand-tear hyaluronic acid, criticizing several brokerage firms for "promoting new favorites," with some Research Reports now inaccessible.
Reporters found that currently, the related Research Reports from Huafu Securities, Western Securities, Ping An Securities, and HTSC can no longer be searched, while the Research Reports from Founder Securities and Sinolink are still available for viewing.
Once known as the "Queen of Hyaluronic Acid," the company's performance has declined sharply, and in response to the collective pessimism from brokerage firms, Bloomage Biotechnology Corporation Limited issued a statement that sparked controversy.
Behind the debate, Bloomage Biotechnology Corporation Limited is undergoing a dual test of Global Strategy transformation and market pressure.
In the capital competition of the medical beauty Industry, who is the center position, Bloomage Biotechnology Corporation Limited or Juzi Biotechnology?
The competition in the Industry will still be lengthy. According to an article from "Investor Network" by Cai Jun, two star companies in the medical beauty field, Bloomage Biotechnology Corporation Limited and Juzi Biotechnology, have stepped into the spotlight of capital. In May, Bloomage Biotechnology Corporation Limited published an article on their official account titled "Concepts Always Reappear, Technology Always Moves Forward". This nearly 5,500-word discussion directly targets the theory that "hyaluronic acid is outdated". Among them, the brokerage Research Reports mentioned Juzi Biotechnology. The competition in the medical beauty Industry has gradually escalated from the product sales of various companies to capital valuation, leading to discussions on technology routes. In the short term, the different circumstances of each listed company have resulted in valuation disparities. In the long term, the Industry...
Bloomage Biotechnology Corporation Limited specifically criticized nine brokerages, stating that "true innovation never fades in the torrent of time."
Sina Technology reported on the afternoon of May 21st that Bloomage Biotechnology Corporation Limited recently published an article on its official WeChat account titled "The Concept Always Replays, Technology Moves Forward Forever," refuting current market viewpoints such as "hyaluronic acid (commonly known as hyaluronic acid) is outdated." In this article, Bloomage Biotechnology directly names nine brokerage firms that have published Research Reports, including Sinolink, HTSC, Founder Securities, Ping An Securities, Western Securities, Anxin Securities, Shenwan Hongyuan Securities, Sinolink Securities, and Huafu Securities, stating that the rise of the "hyaluronic acid is outdated theory" is essentially an illusion created by "impatient capital constructing a thematic illusion." Bloomage Biotechnology emphasizes that hyaluronic acid is
Express News | Bloomage Biotechnology Corporation Limited responds to the "named brokerage" incident: hyaluronic acid has been trampled and vilified.
Express News | Bloomage Biotechnology Corporation Limited refutes the outdated theory of hyaluronic acid and receives support from two major associations.
Bloomage Biotechnology Corporation Limited (688363): Return to positive Net income for the parent company compared to the previous quarter,期待 management reform results.
In the first quarter of 2025, the net income attributable to the parent company increased quarter-on-quarter, and the business of biological active substances and medical terminal operations remained stable. The company achieved revenue of 1.078 billion yuan in the first quarter of 2025, a year-on-year decrease of 20.77%; it achieved net income attributable to the parent company.
Bloomage Biotechnology Corporation Limited (688363): Performance improved compared to Q4 2024, major changes in Global Strategy.
The company released its 25Q1 Earnings Reports, with performance meeting market expectations. In 25Q1, the company's revenue was 1.08 billion yuan, a year-on-year decline of 20.8%; the net income attributable to the parent company was 0.1 billion yuan, a year-on-year decline of 58.1%. The net income attributable to the parent company after deducting non-recurring items was 0.8.
Bloomage Biotechnology Corporation Limited (688363): Deepening reforms lead to short-term pressure, looking forward to a turning point in development in 2025.
Organizational management changes continue to pressure short-term performance, looking forward to the operational turning point in 2025. The company released its annual and quarterly reports: revenue of 5.371 billion yuan in 2024 (year-on-year -11.6%, the same below), and net income attributable to the parent company of 1.
Bloomage Biotechnology Corporation Limited (688363): The first domestic Class III device for water light products has been launched,期待皮肤科学创新转化业务变革成效落地.
The company announced its Q1 report for 2025: In Q1 2025, revenue was 1.078 billion yuan, a year-on-year decrease of 20.77%; net income attributable to shareholders was 0.102 billion yuan, a year-on-year decrease of 58.13%.
Bloomage Biotechnology Corporation Limited (688363): Transformation in progress, "Run Bai Yan·Bo Bo" has been approved to further enrich the medical beauty product matrix.
Event: The company released the Q1 2025 report, with revenue of 1.08 billion yuan for Q1 2025, a year-on-year decrease of 20.8%, and a net income attributable to the parent of 0.1 billion yuan, a year-on-year decrease of 58.1%. Comment: Innovation and transformation in skin science.
Market Insights
Tariff Storm Hits: Hedge with ETFs? Tariff Storm Hits: Hedge with ETFs?
The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios. The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios.
Unlock Now
Discussing
The Sino-US talks are back! How to seize investment opportunities recently?
On June 9 to 10 local time, the first meeting of the China-U.S. economic and trade consultation mechanism was held in London, United Kingdom
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"
Investment Course
Essential Crypto strategies to learn for beginners.
Beginner's Guide: Understand how to invest in Crypto in 3 minutes.
Crypto (Cryptos) is, in simple terms, a virtual currency based on cryptographic principles to ensure transaction security. Unlike the currencies we use daily, C
How to Trade Crypto on Futubull
Step 1: Activate the Cryptos Account. Comprehensive Account > More > Account Management > Activate Trading Products > Select [Cryptos] to start the process. Not
A comprehensive review of crypto history
Have you heard the latest about Bitcoin? In 2024 H1, its value once surged by 68% . As the largest and most well-known cryptocurrency, Bitcoin has increased in